GHDX SEC Filings - Genomic Health, Inc.- Annual Report, Proxy Statement, Prospectus

Basic Stats

LEI	549300QAH59D564PM570
CIK	1131324

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Genomic Health, Inc.

SEC Filings (Chronological Order)

This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.

November 18, 2019	15-12G	GHDX / Genomic Health, Inc. 15-12G - - 15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 000-51541 Genomic Health, Inc. (Exact name of registrant as specified in its
November 13, 2019	SC 13D/A	GHDX / Genomic Health, Inc. / Exact Sciences Corp - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* GENOMIC HEALTH, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 37244C101 (CUSIP Number) Exact Sciences Corporation 441 Charmany Drive Madison, WI 53719 Attn: D. Scott Coward, Senior Vice President, General Counsel, Chief
November 13, 2019	SC 13G	GHDX / Genomic Health, Inc. / ICS OPPORTUNITIES, LTD. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 GENOMIC HEALTH, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 37244C101 (CUSIP Number) NOVEMBER 7, 2019 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to whic
November 8, 2019	EX-3.1	Amended and Restated Certificate of Incorporation of Genomic Health, Inc. Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF GENOMIC HEALTH, INC. Article I The name of the corporation is Genomic Health, Inc. (the “Corporation”). Article II The address of the registered office of the Corporation in the State of Delaware is 251 Little Falls Drive, Wilmington, County of New Castle, Delaware 19808. The name of its registered agent at such address is Corporatio
November 8, 2019	8-K	Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets united states SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 8, 2019 GENOMIC HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-51541 (Commission File Number)
November 8, 2019	EX-3.2	By-Laws of Genomic Health, Inc., as amended Exhibit 3.2 BY-LAWS OF Genomic Health, Inc. A Delaware Corporation Effective November 8, 2019 TABLE OF CONTENTS Page ARTICLE I OFFICES 1 Section 1.1 Registered Office 1 Section 1.2 Other Offices 1 ARTICLE II MEETINGS OF STOCKHOLDERS 1 Section 2.1 Place of Meetings 1 Section 2.2 Annual Meetings 1 Section 2.3 Special Meetings 2 Section 2.4 Notice 2 Section 2.5 Adjournments 3 Section 2.6 Quorum 3 Sec
November 8, 2019	S-8 POS	GHDX / Genomic Health, Inc. S-8 POS - - S-8 POS As filed with the Securities and Exchange Commission on November 8, 2019 Registration No.
November 8, 2019	S-8 POS	GHDX / Genomic Health, Inc. S-8 POS - - S-8 POS S-8 POS 1 a19-223326s8pos.htm S-8 POS As filed with the Securities and Exchange Commission on November 8, 2019 Registration No. 333-128805 Registration No. 333-163006 Registration No. 333-177819 Registration No. 333-207903 Registration No. 333-213079 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-128
November 8, 2019	S-8 POS	GHDX / Genomic Health, Inc. S-8 POS - - S-8 POS As filed with the Securities and Exchange Commission on November 8, 2019 Registration No.
November 8, 2019	S-8 POS	GHDX / Genomic Health, Inc. S-8 POS - - S-8 POS As filed with the Securities and Exchange Commission on November 8, 2019 Registration No.
November 8, 2019	S-8 POS	GHDX / Genomic Health, Inc. S-8 POS - - S-8 POS As filed with the Securities and Exchange Commission on November 8, 2019 Registration No.
November 8, 2019	POS AM	GHDX / Genomic Health, Inc. POS AM - - POS AM As filed with the Securities and Exchange Commission on November 8, 2019 Registration No.
November 8, 2019	POS AM	GHDX / Genomic Health, Inc. POS AM - - POS AM POS AM 1 a19-223321posam.htm POS AM As filed with the Securities and Exchange Commission on November 8, 2019 Registration No. 333-213074 Registration No. 333-213076 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT (REG. NO. 333-213074) FORM S-3 REGISTRATION STATEMENT (REG. NO. 333-213076) UNDER THE SECURITIES
November 7, 2019	EX-99.1	Genomic Health Stockholders Approve Proposed Acquisition by Exact Sciences Exhibit 99.1 Contacts: Investors & Media (U.S.) Emily Faucette Genomic Health +1 650-569-2824 [email protected] [email protected] Genomic Health Stockholders Approve Proposed Acquisition by Exact Sciences REDWOOD CITY, Calif., November 7, 2019 - Genomic Health, Inc. (NASDAQ: GHDX) announced that its stockholders voted to approve the company’s proposed combination with Exact Science
November 7, 2019	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders united states SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2019 GENOMIC HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-51541 (Commission File Number)
October 30, 2019	425	EXAS / EXACT Sciences Corp. 425 - Merger Prospectus - 425 Filed by Exact Sciences Corporation pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Filer: Exact Sciences Corporation Subject Company: Genomic Health, Inc.
October 30, 2019	425	EXAS / EXACT Sciences Corp. 425 - Merger Prospectus - 425 425 1 a19-214261425.htm 425 Filed by Exact Sciences Corporation pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Filer: Exact Sciences Corporation Subject Company: Genomic Health, Inc. SEC File No.: 000-51541 Date: October 29, 2019 Investor Contact: Megan Jones Exact Sciences Corp. [email protected]
October 30, 2019	EX-10.13	Third Amendment to Lease dated January 4, 2007 between the Company and Metropolitan Life Insurance Company. Exhibit 10.13 THIRD AMENDMENT TO LEASE This Third Amendment to Lease (“Amendment”) is entered into, and dated for reference purposes, as of October 4, 2019 (the “Execution Date”) by and between METROPOLITAN LIFE INSURANCE COMPANY, a New York corporation (“Landlord”), and GENOMIC HEALTH, INC., a Delaware corporation (“Tenant”), with reference to the following facts (“Recitals”): A. Landlord and Ten
October 30, 2019	EX-10.14	Third Amendment to Lease dated August 30, 2013 between the Company and Metropolitan Life Insurance Company. Exhibit 10.14 THIRD AMENDMENT TO LEASE This Third Amendment to Lease (“Amendment”) is entered into, and dated for reference purposes, as of October 4, 2019 (the “Execution Date”) by and between METROPOLITAN LIFE INSURANCE COMPANY, a New York corporation (“Landlord”), and GENOMIC HEALTH, INC., a Delaware corporation (“Tenant”), with reference to the following facts (“Recitals”): A. Landlord and Ten
October 30, 2019	10-Q	Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-5154
October 30, 2019	EX-10.15	Second Amendment to Lease dated October 1, 2009 between the Company and Metropolitan Life Insurance Company. Exhibit 10.15 SECOND AMENDMENT TO LEASE This Second Amendment to Lease (“Amendment”) is entered into, and dated for reference purposes, as of October 4, 2019 (the “Execution Date”) by and between METROPOLITAN LIFE INSURANCE COMPANY, a New York corporation (“Landlord”), and GENOMIC HEALTH, INC., a Delaware corporation (“Tenant”), with reference to the following facts (“Recitals”): A. Landlord and T
October 30, 2019	EX-10.12	Fourth Amendment to Lease dated September 23, 2005 between the Company and Metropolitan Life Insurance Company. Exhibit 10.12 FOURTH AMENDMENT TO LEASE This Fourth Amendment to Lease (“Amendment”) is entered into, and dated for reference purposes, as of October 4, 2019 (the “Execution Date”) by and between METROPOLITAN LIFE INSURANCE COMPANY, a New York corporation (“Landlord”), and GENOMIC HEALTH, INC., a Delaware corporation (“Tenant”), with reference to the following facts (“Recitals”): A. Landlord and T
October 30, 2019	EX-10.11	Lease Agreement dated October 4, 2019 between the Company and Metropolitan Life Insurance Company. Exhibit 10.11 LEASE BETWEEN METROPOLITAN LIFE INSURANCE COMPANY (LANDLORD) AND GENOMIC HEALTH, INC. (TENANT) SEAPORT CENTRE Redwood City, California TABLE OF CONTENTS PAGE ARTICLE ONE - BASIC LEASE PROVISIONS 1 1.01 BASIC LEASE PROVISIONS 1 1.02 ENUMERATION OF EXHIBITS & RIDER(S) 2 1.03 DEFINITIONS 3 ARTICLE TWO - PREMISES, TERM, FAILURE TO GIVE POSSESSION, COMMON AREAS AND PARKING 7 2.01 LEASE OF
October 30, 2019	EX-10.16	First Amendment to Lease dated November 11, 2015 between the Company and Metropolitan Life Insurance Company. EX-10.16 7 ex-10d16.htm EX-10.16 Exhibit 10.16 FIRST AMENDMENT TO LEASE This First Amendment to Lease (“Amendment”) is entered into, and dated for reference purposes, as of October 4, 2019 (the “Execution Date”) by and between METROPOLITAN LIFE INSURANCE COMPANY, a New York corporation (“Landlord”), and GENOMIC HEALTH, INC., a Delaware corporation (“Tenant”), with reference to the following facts
October 28, 2019	425	GHDX / Genomic Health, Inc. 425 - Merger Prospectus - 425 united states SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 28, 2019 GENOMIC HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-51541 (Commission File Number)
October 28, 2019	8-K	Other Events united states SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 28, 2019 GENOMIC HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-51541 (Commission File Number)
October 28, 2019	425	GHDX / Genomic Health, Inc. 425 - Merger Prospectus - 425 Filed by Genomic Health, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Filer: Genomic Health, Inc. Subject Company: Genomic Health, Inc, SEC File No.: 000-51541 Date: October 28, 2019 The following email was sent to the employees of Genomic Health, Inc. by G. Bradley Cole, Chief Financial Officer of Gen
October 28, 2019	425	EXAS / EXACT Sciences Corp. 425 - Merger Prospectus - 425 Filed by Exact Sciences Corporation pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Filer: Exact Sciences Corporation Subject Company: Genomic Health, Inc.
October 4, 2019	DEFM14A	GHDX / Genomic Health, Inc. DEFM14A - - DEFM14A Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
September 11, 2019	425	GHDX / Genomic Health, Inc. 425 - Merger Prospectus - 425 united states SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2019 GENOMIC HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware (State or Other Jurisdiction of Incorporation) 000-51541 (Commission File Number
September 11, 2019	8-K	Other Events united states SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2019 GENOMIC HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware (State or Other Jurisdiction of Incorporation) 000-51541 (Commission File Number
September 5, 2019	425	EXAS / EXACT Sciences Corp. 425 - Merger Prospectus - 425 Filed by Exact Sciences Corporation pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Filer: Exact Sciences Corporation Subject Company: Genomic Health, Inc.
August 16, 2019	425	GHDX / Genomic Health, Inc. 425 - Merger Prospectus - 425 Filed by Genomic Health, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Filer: Genomic Health, Inc. Subject Company: Genomic Health, Inc, SEC File No.: 000-51541 Date: August 15, 2019 GENOMIC HEALTH, INC. Supplemental Employee Q&A (Vice President Level & Above) As you are aware, on July 28, 2019, Exact S
August 12, 2019	425	EXAS / EXACT Sciences Corp. 425 - Merger Prospectus - 425 Filed by Exact Sciences Corporation pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Filer: Exact Sciences Corporation Subject Company: Genomic Health, Inc.
August 8, 2019	425	EXAS / EXACT Sciences Corp. 425 - Merger Prospectus - 425 Filed by Exact Sciences Corporation pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Filer: Exact Sciences Corporation Subject Company: Genomic Health, Inc.
August 7, 2019	SC 13D	GHDX / Genomic Health, Inc. / Exact Sciences Corp - SC 13D Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* GENOMIC HEALTH, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 37244C101 (CUSIP Number) Exact Sciences Corporation 441 Charmany Drive Madison, WI 53719 Attn: D. Scott Coward, Senior Vice President, General Counsel, Chief
August 6, 2019	10-Q	Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-51541 GEN
August 3, 2019	425	GHDX / Genomic Health, Inc. 425 - Merger Prospectus - 425 Filed by Genomic Health, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Filer: Genomic Health, Inc. Subject Company: Genomic Health, Inc, SEC File No.: 000-51541 Date: August 2, 2019 GENOMIC HEALTH, INC. Employee Q&A As you are aware, on July 28, 2019, Exact Sciences and Genomic Health entered into a def
August 1, 2019	425	EXAS / EXACT Sciences Corp. 425 - Merger Prospectus - 425 Filed by Exact Sciences Corporation pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Filer: Exact Sciences Corporation Subject Company: Genomic Health, Inc.
August 1, 2019	425	GHDX / Genomic Health, Inc. 425 - Merger Prospectus - 425 Filed by Genomic Health, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Filer: Genomic Health, Inc. Subject Company: Genomic Health, Inc, SEC File No.: 000-51541 Date: July 31, 2019 [Email from Kim Popovits] Hi All, It was great connecting with you at our All Employee Meeting yesterday to share our excit
July 31, 2019	425	EXAS / EXACT Sciences Corp. 425 - Merger Prospectus - 425 425 1 a19-1526513425.htm 425 Filed by Exact Sciences Corporation pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Filer: Exact Sciences Corporation Subject Company: Genomic Health, Inc. SEC File No.: 000-51541 Date: July 31, 2019 The following letter was sent to Genomic Health, Inc. employees: Genomic Health Te
July 31, 2019	425	GHDX / Genomic Health, Inc. 425 - Merger Prospectus - 425 Filed by Genomic Health, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Filer: Genomic Health, Inc. Subject Company: Genomic Health, Inc, SEC File No.: 000-51541 Date: July 31, 2019 Genomic Health 20,846 followers 15h Exciting times here at Genomic Health! We are excited to partner with Exact Sciences. F
July 31, 2019	425	GHDX / Genomic Health, Inc. 425 - Merger Prospectus - 425 Filed by Genomic Health, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Filer: Genomic Health, Inc. Subject Company: Genomic Health, Inc, SEC File No.: 000-51541 Date: July 31, 2019 [International] Dear Valued Genomic Health Partner, I am reaching out to share the exciting news that we have signed an agr
July 31, 2019	425	GHDX / Genomic Health, Inc. 425 - Merger Prospectus - 425 Filed by Genomic Health, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Filer: Genomic Health, Inc. Subject Company: Genomic Health, Inc, SEC File No.: 000-51541 Date: July 30, 2019 All-Employee Meeting July 30, 2019 Q2 2019 Financial Results Brad Cole 2 Creating a high-growth leader to detect cancer ear
July 31, 2019	SC 13D/A	GHDX / Genomic Health, Inc. / Baker Brothers Advisors LP - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 42) Genomic Health, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 37244C101 (CUSIP Number) Alexandra A. Toohey Chief Financial Officer Baker Bros. Advisors LP 860 Washington Street, 3rd Floor New York, NY 1001
July 30, 2019	425	EXAS / EXACT Sciences Corp. 425 - Merger Prospectus - 425 425 1 a19-1526512425.htm 425 Filed by Exact Sciences Corporation pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Filer: Exact Sciences Corporation Subject Company: Genomic Health, Inc. SEC File No.: 000-51541 Date: July 30, 2019 All-Employee Meeting July 30, 2019 Q2 2019 Financial Results Brad Cole 2 Creating
July 30, 2019	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2019 GENOMIC HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 000-51541 77-0552594 (State or Other Jurisdiction of Incorporation) (Commission File
July 30, 2019	EX-99.3	VOTING AGREEMENT Exhibit 99.3 VOTING AGREEMENT This VOTING AGREEMENT, dated as of July 28, 2019 (this “Agreement”), is made and entered into by and among Exact Sciences Corporation, a Delaware Corporation (“Parent”), [·] (the “Advisor”), and the undersigned stockholder (the “Stockholder”) of Genomic Health, Inc., a Delaware corporation (the “Company”). Parent, Advisor and the Stockholder are referred to individual
July 30, 2019	EX-99.1	VOTING AGREEMENT Exhibit 99.1 VOTING AGREEMENT This VOTING AGREEMENT, dated as of July 28, 2019 (this “Agreement”), is made and entered into by and among Exact Sciences Corporation, a Delaware Corporation (“Parent”), [·] (the “Advisor”), and the undersigned stockholder (the “Stockholder”) of Genomic Health, Inc., a Delaware corporation (the “Company”). Parent, Advisor and the Stockholder are referred to individual
July 30, 2019	EX-2.1	Agreement and Plan of Merger, dated as of July 28, 2019, by and among Exact Sciences Corporation, Spring Acquisition Corp. and Genomic Health, Inc. (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed by Genomic Health, Inc. on July 30, 2019)* EX-2.1 2 a19-162653ex2d1.htm EX-2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER By and Among EXACT SCIENCES CORPORATION SPRING ACQUISITION CORP. and GENOMIC HEALTH, INC. Dated as of July 28, 2019 TABLE OF CONTENTS Page ARTICLE I THE MERGER Section 1.1 The Merger 1 Section 1.2 The Closing 2 Section 1.3 Effective Time 2 Section 1.4 Certificate of Incorporation; Bylaws 2 Section 1.5 Board of Directors;
July 30, 2019	EX-99.2	VOTING AGREEMENT Exhibit 99.2 VOTING AGREEMENT This VOTING AGREEMENT, dated as of July 28, 2019 (this “Agreement”), is made and entered into by and among Exact Sciences Corporation, a Delaware Corporation (“Parent”), and the undersigned stockholder (the “Stockholder”) of Genomic Health, Inc., a Delaware corporation (the “Company”). Parent and the Stockholder are referred to individually as a “Party” and collective
July 30, 2019	425	GHDX / Genomic Health, Inc. 425 - Merger Prospectus - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2019 GENOMIC HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 000-51541 77-0552594 (State or Other Jurisdiction of Incorporation) (Commission File
July 30, 2019	EX-99.1	VOTING AGREEMENT Exhibit 99.1 VOTING AGREEMENT This VOTING AGREEMENT, dated as of July 28, 2019 (this “Agreement”), is made and entered into by and among Exact Sciences Corporation, a Delaware Corporation (“Parent”), [·] (the “Advisor”), and the undersigned stockholder (the “Stockholder”) of Genomic Health, Inc., a Delaware corporation (the “Company”). Parent, Advisor and the Stockholder are referred to individual
July 30, 2019	EX-99.2	VOTING AGREEMENT Exhibit 99.2 VOTING AGREEMENT This VOTING AGREEMENT, dated as of July 28, 2019 (this “Agreement”), is made and entered into by and among Exact Sciences Corporation, a Delaware Corporation (“Parent”), and the undersigned stockholder (the “Stockholder”) of Genomic Health, Inc., a Delaware corporation (the “Company”). Parent and the Stockholder are referred to individually as a “Party” and collective
July 30, 2019	EX-99.3	VOTING AGREEMENT Exhibit 99.3 VOTING AGREEMENT This VOTING AGREEMENT, dated as of July 28, 2019 (this “Agreement”), is made and entered into by and among Exact Sciences Corporation, a Delaware Corporation (“Parent”), [·] (the “Advisor”), and the undersigned stockholder (the “Stockholder”) of Genomic Health, Inc., a Delaware corporation (the “Company”). Parent, Advisor and the Stockholder are referred to individual
July 30, 2019	EX-2.1	Agreement and Plan of Merger, dated as of July 28, 2019, by and among Exact Sciences Corporation, Spring Acquisition Corp. and Genomic Health, Inc.* Exhibit 2.1 AGREEMENT AND PLAN OF MERGER By and Among EXACT SCIENCES CORPORATION SPRING ACQUISITION CORP. and GENOMIC HEALTH, INC. Dated as of July 28, 2019 TABLE OF CONTENTS Page ARTICLE I THE MERGER Section 1.1 The Merger 1 Section 1.2 The Closing 2 Section 1.3 Effective Time 2 Section 1.4 Certificate of Incorporation; Bylaws 2 Section 1.5 Board of Directors; Officers 2 ARTICLE II EFFECT OF THE
July 30, 2019	EX-99.3	VOTING AGREEMENT Exhibit 99.3 VOTING AGREEMENT This VOTING AGREEMENT, dated as of July 28, 2019 (this “Agreement”), is made and entered into by and among Exact Sciences Corporation, a Delaware Corporation (“Parent”), [·] (the “Advisor”), and the undersigned stockholder (the “Stockholder”) of Genomic Health, Inc., a Delaware corporation (the “Company”). Parent, Advisor and the Stockholder are referred to individual
July 30, 2019	EX-99.2	VOTING AGREEMENT Exhibit 99.2 VOTING AGREEMENT This VOTING AGREEMENT, dated as of July 28, 2019 (this “Agreement”), is made and entered into by and among Exact Sciences Corporation, a Delaware Corporation (“Parent”), and the undersigned stockholder (the “Stockholder”) of Genomic Health, Inc., a Delaware corporation (the “Company”). Parent and the Stockholder are referred to individually as a “Party” and collective
July 30, 2019	EX-2.1	Agreement and Plan of Merger, dated as of July 28, 2019, by and among Exact Sciences Corporation, Spring Acquisition Corp. and Genomic Health, Inc.* Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER By and Among EXACT SCIENCES CORPORATION SPRING ACQUISITION CORP. and GENOMIC HEALTH, INC. Dated as of July 28, 2019 TABLE OF CONTENTS Page ARTICLE I THE MERGER Section 1.1 The Merger 1 Section 1.2 The Closing 2 Section 1.3 Effective Time 2 Section 1.4 Certificate of Incorporation; Bylaws 2 Section 1.5 Board of Directors; Officers 2 Article
July 30, 2019	EX-99.1	VOTING AGREEMENT Exhibit 99.1 VOTING AGREEMENT This VOTING AGREEMENT, dated as of July 28, 2019 (this “Agreement”), is made and entered into by and among Exact Sciences Corporation, a Delaware Corporation (“Parent”), [·] (the “Advisor”), and the undersigned stockholder (the “Stockholder”) of Genomic Health, Inc., a Delaware corporation (the “Company”). Parent, Advisor and the Stockholder are referred to individual
July 30, 2019	425	EXAS / EXACT Sciences Corp. 425 - Merger Prospectus - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2019 EXACT SCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-35092 02-0478229 (State or other jurisdiction (Commission File Number) (IR
July 30, 2019	425	GHDX / Genomic Health, Inc. 425 - Merger Prospectus - 425 Filed by Genomic Health, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Filer: Genomic Health, Inc. Subject Company: Genomic Health, Inc, SEC File No.: 000-51541 Date: July 30, 2019 Corrected Transcript 29-J ul -20 19 EXACT Sciences Corp. (EX A S ) Genomic Health and EXACT Sciences Corp. Merger Call - Q2
July 30, 2019	425	EXAS / EXACT Sciences Corp. 425 - Merger Prospectus - 425 Filed by Exact Sciences Corporation pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Filer: Exact Sciences Corporation Subject Company: Genomic Health, Inc.
July 30, 2019	425	EXAS / EXACT Sciences Corp. 425 - Merger Prospectus - 425 Filed by Exact Sciences Corporation pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Filer: Exact Sciences Corporation Subject Company: Genomic Health, Inc.
July 30, 2019	425	EXAS / EXACT Sciences Corp. 425 - Merger Prospectus - 425 425 1 a19-152656425.htm 425 Filed by Exact Sciences Corporation pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Filer: Exact Sciences Corporation Subject Company: Genomic Health, Inc. SEC File No.: 000-51541 Date: July 29, 2019 Corrected Transcript 29-J ul -20 19 EXACT Sciences Corp. (EX A S ) Genomic Health a
July 29, 2019	425	EXAS / EXACT Sciences Corp. 425 - Merger Prospectus - 425 Filed by Exact Sciences Corporation pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Filer: Exact Sciences Corporation Subject Company: Genomic Health, Inc.
July 29, 2019	425	EXAS / EXACT Sciences Corp. 425 - Merger Prospectus - 425 425 1 a19-152659425.htm 425 Filed by Exact Sciences Corporation pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Filer: Exact Sciences Corporation Subject Company: Genomic Health, Inc. SEC File No.: 000-51541 Date: July 29, 2019 The following FAQ was sent to Exact Sciences Corporation employees: EXAS Team FAQ 1
July 29, 2019	425	EXAS / EXACT Sciences Corp. 425 - Merger Prospectus - 425 Filed by Exact Sciences Corporation pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Filer: Exact Sciences Corporation Subject Company: Genomic Health, Inc.
July 29, 2019	425	EXAS / EXACT Sciences Corp. 425 - Merger Prospectus - 425 Filed by Exact Sciences Corporation pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Filer: Exact Sciences Corporation Subject Company: Genomic Health, Inc.
July 29, 2019	425	GHDX / Genomic Health, Inc. 425 - Merger Prospectus - 425 425 1 a19-1626511425.htm 425 Filed by Genomic Health, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Filer: Genomic Health, Inc. Subject Company: Genomic Health, Inc, SEC File No.: 000-51541 Date: July 29, 2019 Exact Scrences•Cenom•c Health COMBINING TO CREATE A LEADING GLOBAL CANCER DIAGNOSTICS COMPANY
July 29, 2019	425	GHDX / Genomic Health, Inc. 425 - Merger Prospectus - 425 Filed by Genomic Health, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Filer: Genomic Health, Inc. Subject Company: Genomic Health, Inc, SEC File No.: 000-51541 Date: July 29, 2019 Dear Valued Genomic Health Partner, I am reaching out to share the exciting news that we have signed an agreement to combin
July 29, 2019	425	GHDX / Genomic Health, Inc. 425 - Merger Prospectus - 425 Filed by Genomic Health, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Filer: Genomic Health, Inc. Subject Company: Genomic Health, Inc, SEC File No.: 000-51541 Date: July 29, 2019 Dear INSERT, I am pleased to share some exciting news about Genomic Health. We announced an agreement to combine with Exact
July 29, 2019	425	GHDX / Genomic Health, Inc. 425 - Merger Prospectus - 425 Filed by Genomic Health, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Filer: Genomic Health, Inc. Subject Company: Genomic Health, Inc, SEC File No.: 000-51541 Date: July 29, 2019 Frequently Asked Questions 1. What was announced? · Exact Sciences and Genomic Health have entered into a definitive agreem
July 29, 2019	425	GHDX / Genomic Health, Inc. 425 - Merger Prospectus - 425 425 1 a19-162658425.htm 425 Filed by Genomic Health, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Filer: Genomic Health, Inc. Subject Company: Genomic Health, Inc, SEC File No.: 000-51541 Date: July 29, 2019 Combining to Create a Leading Global Cancer Diagnostics Company CREATING HIGH-GROWTH LEADER TO
July 29, 2019	425	GHDX / Genomic Health, Inc. 425 - Merger Prospectus - 425 Filed by Genomic Health, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Filer: Genomic Health, Inc. Subject Company: Genomic Health, Inc, SEC File No.: 000-51541 Date: July 29, 2019 Dear All, For nearly 20 years, Genomic Health has been committed to our vision to revolutionize the way cancer is diagnosed
July 29, 2019	425	GHDX / Genomic Health, Inc. 425 - Merger Prospectus - 425 Filed by Genomic Health, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Filer: Genomic Health, Inc. Subject Company: Genomic Health, Inc, SEC File No.: 000-51541 Date: July 29, 2019 CREATING A LEADING GLOBAL CANCER DIAGNOSTICS COMPANY July 29, 2019 Exact Sciences + Genomic Health 2 2 Safe Harbor Statemen
July 29, 2019	425	EXAS / EXACT Sciences Corp. 425 - Merger Prospectus - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2019 EXACT SCIENCES CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-35092 02-0478229 (State or Other Jurisdiction of Incorporation) (Commission Fi
July 29, 2019	EX-99	Second-quarter revenue increased 94 percent to $200 million and Cologuard test volume increased 93 percent to 415,000 Exhibit 99 Investor Contact: Megan Jones Exact Sciences Corp. [email protected] 608-535-8815 For Immediate Release Second-quarter revenue increased 94 percent to $200 million and Cologuard test volume increased 93 percent to 415,000 · Estimated Cologuard® market share increased to 5.7 percent during the second quarter · More than 13,000 health care providers ordered their initial Cologu
July 29, 2019	EX-99.1	EXACT SCIENCES AND GENOMIC HEALTH TO COMBINE, CREATING LEADING GLOBAL CANCER DIAGNOSTICS COMPANY Joins two of the strongest brands in cancer diagnostics, Cologuard® and Oncotype DX®, providing a strong platform for continued growth Forms best-in-clas Exhibit 99.1 EXACT SCIENCES AND GENOMIC HEALTH TO COMBINE, CREATING LEADING GLOBAL CANCER DIAGNOSTICS COMPANY Joins two of the strongest brands in cancer diagnostics, Cologuard® and Oncotype DX®, providing a strong platform for continued growth Forms best-in-class commercial, research, development and clinical organization, with enhanced scale and scope in cancer diagnostics Global infrastructure
July 29, 2019	425	EXAS / EXACT Sciences Corp. 425 - Merger Prospectus - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2019 EXACT SCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-35092 (Commission File Numb
July 29, 2019	EX-99.1	EXACT SCIENCES AND GENOMIC HEALTH TO COMBINE, CREATING LEADING GLOBAL CANCER DIAGNOSTICS COMPANY Joins two of the strongest brands in cancer diagnostics, Cologuard® and Oncotype DX®, providing a strong platform for continued growth Forms best-in-clas Exhibit 99.1 EXACT SCIENCES AND GENOMIC HEALTH TO COMBINE, CREATING LEADING GLOBAL CANCER DIAGNOSTICS COMPANY Joins two of the strongest brands in cancer diagnostics, Cologuard® and Oncotype DX®, providing a strong platform for continued growth Forms best-in-class commercial, research, development and clinical organization, with enhanced scale and scope in cancer diagnostics Global infrastructure
July 29, 2019	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2019 GENOMIC HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware (State or Other Jurisdiction of Incorporation) 000-51541 (Commission File Number) 77
July 29, 2019	425	GHDX / Genomic Health, Inc. 425 - Merger Prospectus - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2019 GENOMIC HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware (State or Other Jurisdiction of Incorporation) 000-51541 (Commission File Number) 77
July 29, 2019	EX-99.1	EXACT SCIENCES AND GENOMIC HEALTH TO COMBINE, CREATING LEADING GLOBAL CANCER DIAGNOSTICS COMPANY Joins two of the strongest brands in cancer diagnostics, Cologuard® and Oncotype DX®, providing a strong platform for continued growth Forms best-in-clas Exhibit 99.1 EXACT SCIENCES AND GENOMIC HEALTH TO COMBINE, CREATING LEADING GLOBAL CANCER DIAGNOSTICS COMPANY Joins two of the strongest brands in cancer diagnostics, Cologuard® and Oncotype DX®, providing a strong platform for continued growth Forms best-in-class commercial, research, development and clinical organization, with enhanced scale and scope in cancer diagnostics Global infrastructure
July 29, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2019 GENOMIC HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware (State or Other Jurisdiction of Incorporation) 000-51541 (Commission File Number) 77
July 29, 2019	EX-99.1	Genomic Health Reports 19% Revenue Growth and Record Profit in Second Quarter 2019, Raises Full-Year Guidance Delivered $114.1M in Revenue and Growth of 19.4% in the Second Quarter Reported $16.0M in Profit and EPS of $0.42 Per Share on a Diluted Bas Exhibit 99.1 Contact: Investors & Media Emily Faucette Genomic Health 650-569-2824 [email protected] [email protected] Genomic Health Reports 19% Revenue Growth and Record Profit in Second Quarter 2019, Raises Full-Year Guidance Delivered $114.1M in Revenue and Growth of 19.4% in the Second Quarter Reported $16.0M in Profit and EPS of $0.42 Per Share on a Diluted Basis Raises Full-
June 18, 2019	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2019 GENOMIC HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 000-51541 77-0552594 (State or other jurisdiction (Commission (IRS Employer of incor
May 15, 2019	DEFA14A	GHDX / Genomic Health, Inc. DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin
May 9, 2019	10-Q	Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 Or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-51541 GENO
May 9, 2019	EX-10.13	Sublease between the Company and Acelrx Pharmaceuticals, Inc., dated as of January 3, 2019. EX-10.13 2 ghdx-20190331ex1013f9546.htm EX-10.13 Exhibit 10.13 SUBLEASE THIS SUBLEASE (this “Sublease”), dated for reference purposes only as of November 30, 2018 (the “Execution Date”), is made by and between ACELRX PHARMACEUTICALS, INC., a Delaware corporation (“Sublandlord”), and GENOMIC HEALTH, INC., a Delaware corporation (“Subtenant”). RECITALS WHEREAS, Sublandlord and Metropolitan Life Insu
May 7, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2019 GENOMIC HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 000-51541 77-0552594 (State or other jurisdiction (Commission (IRS Employer of incorpo
May 7, 2019	EX-99.1	Genomic Health Reports First Quarter 2019 Financial Results and Recent Business Progress Delivered $108.8M in Revenue and Growth of 17.4 Percent Achieved Significant Revenue Growth for All Key Product Areas Reported $13.0M in Profit and EPS of $0.34 Exhibit 99.1 Contact: Investors & Media: Emily Faucette Genomic Health 650-569-2824 [email protected] [email protected] Genomic Health Reports First Quarter 2019 Financial Results and Recent Business Progress Delivered $108.8M in Revenue and Growth of 17.4 Percent Achieved Significant Revenue Growth for All Key Product Areas Reported $13.0M in Profit and EPS of $0.34 Per Share on a
April 26, 2019	CORRESP	GHDX / Genomic Health, Inc. CORRESP - - Genomic Health, Inc. 301 Penobscot Drive Redwood City, California 94063 April 26, 2019 Mr. Brian McAllister Office of Beverages, Apparel and Mining United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Genomic Health, Inc. Form 10-K for the Fiscal Year Ended December 31, 2017 Form 8-K filed on November 6, 2018 File No. 000-51
April 25, 2019	DEF 14A	Amended and Restated Genomic Health, Inc. 2005 Stock Incentive Plan (incorporated by reference filed together with the Company’s definitive proxy statement on Schedule 14A, filed on April 25, 2019). UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☒ Defin
April 12, 2019	SC 13D/A	GHDX / Genomic Health, Inc. / Baker Brothers Advisors LP - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 41) Genomic Health, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 37244C101 (CUSIP Number) Alexandra A. Toohey Chief Financial Officer Baker Bros. Advisors LP 860 Washington Street, 3rd Floor New York, NY 1001
March 25, 2019	SC 13D/A	GHDX / Genomic Health, Inc. / Baker Brothers Advisors LP - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 40) Genomic Health, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 37244C101 (CUSIP Number) Alexandra A. Toohey Chief Financial Officer Baker Bros. Advisors LP 860 Washington Street, 3rd Floor New York, NY 1001
March 14, 2019	SC 13D/A	GHDX / Genomic Health, Inc. / Baker Brothers Advisors LP - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 39) Genomic Health, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 37244C101 (CUSIP Number) Alexandra A. Toohey Chief Financial Officer Baker Bros. Advisors LP 860 Washington Street, 3rd Floor New York, NY 1001
February 28, 2019	EX-99.2	Loan Agreement Between Baker Brothers Life Sciences, L.P., 667, L.P. and Baker Bros. Advisors LP Exhibit 99.2 Loan Agreement Between Baker Brothers Life Sciences, L.P., 667, L.P. and Baker Bros. Advisors LP For value received, Baker Bros Advisors LP (the “Management Company”) promises to pay Baker Brothers Life Sciences, L.P. and 667, L.P., (collectively “The Funds”), the amounts set forth in Schedule A below, payable on the Due Date (as defined below) with interest payable through the Due Da
February 28, 2019	10-K	the audited consolidated financial statements of Genomic Health as of and for the year ended December 31, 2018 and the related notes, included in Genomic Health's Annual Report on Form 10-K for the fiscal year ended December 31, 2018; and 10-K 1 ghdx-20181231x10k.htm 10-K Table of Contents taxane UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10‑K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2018 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition per
February 28, 2019	EX-21.1	List of Subsidiaries. EX-21.1 2 ghdx-20181231ex21174163d.htm EX-21.1 Exhibit 21.1 GENOMIC HEALTH, INC. SUBSIDIARIES (as of December 31, 2018) Genomic Health International Holdings, LLC—100% owned by Genomic Heath, Inc. Oncotype Laboratories, Inc. (inactive)—100% owned by Genomic Health, Inc. Genomic Health International Sarl—100% owned by Genomic Health International Holdings, LLC Genomic Health UK, Ltd—100% owned by G
February 28, 2019	SC 13D/A	GHDX / Genomic Health, Inc. / Baker Brothers Advisors LP - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 38) Genomic Health, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 37244C101 (CUSIP Number) Alexandra A. Toohey Chief Financial Officer Baker Bros. Advisors LP 860 Washington Street, 3rd Floor New York, NY 1001
February 28, 2019	EX-99.1	PROCEEDS AGREEMENT EX-99.1 2 tv515111ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 PROCEEDS AGREEMENT AGREEMENT dated as of February 25, 2019 by and between Baker Bros. Advisors LP (the “Management Company”) and Julian Baker (the “Agent”). WHEREAS, the Agent, in his capacity as a director of Genomic Health, Inc. (the “Company”), received non-transferable options (the “Options”) to purchase 8,250 shares of the Company common
February 26, 2019	CORRESP	GHDX / Genomic Health, Inc. CORRESP - - Genomic Health, Inc. 301 Penobscot Drive Redwood City, California 94063 February 26, 2019 Mr. Brian McAllister Office of Beverages, Apparel and Mining United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Genomic Health, Inc. Form 10-K for the Fiscal Year Ended December 31, 2017 Form 8-K filed on November 6, 2018 File No. 000
February 20, 2019	EX-99.1	Genomic Health Reports Record 2018 Fourth Quarter and Year-end Financial Results and Provides 2019 Financial Guidance Delivered $394.1M in Full-year Revenue and Growth of 18 Percent for the Full Year Reported Full-year Profit of $25.7M on a GAAP Basi Exhibit 99.1 Contacts: Investors: Emily Faucette Genomic Health 650-569-2824 [email protected] Media: Victoria Steiner Genomic Health 415-370-5804 [email protected] Genomic Health Reports Record 2018 Fourth Quarter and Year-end Financial Results and Provides 2019 Financial Guidance Delivered $394.1M in Full-year Revenue and Growth of 18 Percent for the Full Year Reported Full-year
February 20, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2019 GENOMIC HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 000-51541 77-0552594 (State or other jurisdiction (Commission (IRS Employer of i
February 14, 2019	SC 13G/A	GHDX / Genomic Health, Inc. / Camber Capital Management LLC - PRIMARY DOCUMENT Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) Genomic Health Inc. (Name of Issuer) Common Shares $0.0001 par value (Title of Class of Securities) 37244C101 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant
February 14, 2019	EX-1	JOINT FILING AGREEMENT EXHIBIT 1 JOINT FILING AGREEMENT This Joint Filing Agreement dated February 14, 2019 is by and between Camber Capital Management LP, a Delaware limited partnership, and Stephen DuBois, an individual (the foregoing are collectively referred to herein as the "Filers").
February 11, 2019	SC 13G	GHDX / Genomic Health, Inc. / VANGUARD GROUP INC Passive Investment genomichealthinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 0 )* Name of issuer: Genomic Health Inc Title of Class of Securities: Common Stock CUSIP Number: 37244C101 Date of Event Which Requires Filing of this Statement: December 31, 2018 Check the appropriate box
February 8, 2019	CORRESP	GHDX / Genomic Health, Inc. CORRESP - - Genomic Health, Inc. 301 Penobscot Drive Redwood City, California 94063 February 8, 2019 Mr. Brian McAllister Office of Beverages, Apparel and Mining United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Genomic Health, Inc. Form 10-K for the Fiscal Year Ended December 31, 2017 Form 8-K filed on November 6, 2018 File No. 000-
February 1, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2019 (January 29, 2019) GENOMIC HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 000-51541 77-0552594 (State or other jurisdiction (Commission
February 1, 2019	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2019 (January 29, 2019) GENOMIC HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 000-51541 77-0552594 (State or other jurisdiction (Commission
February 1, 2019	EX-3.1	Amended and Restated Bylaws of the Company, as amended January29, 2019 (incorporated by reference to exhibit 3.1 to the Company’s Current Report on Form 8‑K filed on February 1, 2019). EX-3.1 2 a19-39091ex3d1.htm EX-3.1 Exhibit 3.1 AMENDED AND RESTATED B Y L A W S OF GENOMIC HEALTH, INC. (a Delaware corporation) (as amended on January 29, 2019) TABLE OF CONTENTS Page ARTICLE 1 Offices 1 1.1 Registered Office 1 1.2 Other Offices 1 ARTICLE 2 Meeting of Stockholders 1 2.1 Place of Meeting 1 2.2 Annual Meeting 1 2.3 Special Meetings 4 2.4 Notice of Meetings 4 2.5 List of Stockholder
January 22, 2019	SC 13D/A	GHDX / Genomic Health, Inc. / Baker Brothers Advisors LP - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 37) Genomic Health, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 37244C101 (CUSIP Number) Alexandra A. Toohey Chief Financial Officer Baker Bros. Advisors LP 860 Washington Street, 3rd Floor New York, NY 1001
December 3, 2018	SC 13D/A	GHDX / Genomic Health, Inc. / Baker Brothers Advisors LP - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 36) Genomic Health, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 37244C101 (CUSIP Number) Alexandra A. Toohey Chief Financial Officer Baker Bros. Advisors LP 860 Washington Street, 3rd Floor New York, NY 1001
November 28, 2018	SC 13D/A	GHDX / Genomic Health, Inc. / Baker Brothers Advisors LP - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 35) Genomic Health, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 37244C101 (CUSIP Number) Alexandra A. Toohey Chief Financial Officer Baker Bros. Advisors LP 860 Washington Street, 3rd Floor New York, NY 1001
November 13, 2018	SC 13D/A	GHDX / Genomic Health, Inc. / Baker Brothers Advisors LP - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 34) Genomic Health, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 37244C101 (CUSIP Number) Alexandra A. Toohey Chief Financial Officer Baker Bros. Advisors LP 860 Washington Street, 3rd Floor New York, NY 1001
November 8, 2018	10-Q	GHDX / Genomic Health, Inc. 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 Or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-51541
November 6, 2018	EX-99.1	Genomic Health Announces Record Revenue and Profit in Third Quarter 2018 Financial Results; Raises Full Year Guidance Reported $101M in Revenue and Delivered 23 Percent Growth on a Pre-606 Adjusted Revenue Basis Delivered $12M Profit on a GAAP Basis; Exhibit 99.1 Contacts: Investors: Emily Faucette Genomic Health 650-569-2824 [email protected] Media: Victoria Steiner Genomic Health 415-370-5804 [email protected] Genomic Health Announces Record Revenue and Profit in Third Quarter 2018 Financial Results; Raises Full Year Guidance Reported $101M in Revenue and Delivered 23 Percent Growth on a Pre-606 Adjusted Revenue Basis Deliver
November 6, 2018	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2018 GENOMIC HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 000-51541 77-0552594 (State or other jurisdiction (Commission (IRS Employer of in
August 7, 2018	10-Q	GHDX / Genomic Health, Inc. 10-Q (Quarterly Report) 10-Q 1 ghdx-20180630x10q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 Or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commi
August 2, 2018	EX-99.1	Genomic Health Announces Second Quarter 2018 Financial Results and Reports Recent Business Progress Reported Record Revenue of $95.6M and Delivered 14 Percent Growth on a Pre-606 Adjusted Revenue Basis Delivered $8.3M Profit on a GAAP Basis and $9.4M Exhibit 99.1 Investor and Media Contact: Emily Faucette Genomic Health 650-569-2824 [email protected] Genomic Health Announces Second Quarter 2018 Financial Results and Reports Recent Business Progress Reported Record Revenue of $95.6M and Delivered 14 Percent Growth on a Pre-606 Adjusted Revenue Basis Delivered $8.3M Profit on a GAAP Basis and $9.4M Profit on a Non-GAAP Basis 12th Conse
August 2, 2018	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2018 GENOMIC HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 000-51541 77-0552594 (State or other jurisdiction (Commission (IRS Employer of inco
June 11, 2018	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2018 GENOMIC HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 000-51541 77-0552594 (State or other jurisdiction (Commission (IRS Employer of incorp
May 9, 2018	10-Q	GHDX / Genomic Health, Inc. 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 Or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-51541 GENO
May 2, 2018	EX-99.1	Genomic Health Announces First Quarter 2018 Financial Results and Reports Recent Business Progress Reported Record Revenue of $92.6M and Delivered 13 Percent Revenue Growth on a Pre-606 Adjusted Basis Reported Net Loss of $3.8M Including First Quarte Exhibit 99.1 Contacts: Investors : Emily Faucette Genomic Health 650-569-2824 [email protected] Media: Victoria Steiner Genomic Health 415-370-5804 [email protected] Genomic Health Announces First Quarter 2018 Financial Results and Reports Recent Business Progress Reported Record Revenue of $92.6M and Delivered 13 Percent Revenue Growth on a Pre-606 Adjusted Basis Reported Net Loss
May 2, 2018	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2018 GENOMIC HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 000-51541 77-0552594 (State or other jurisdiction (Commission (IRS Employer of incorpo
April 27, 2018	DEF 14A	Amended and Restated Genomic Health, Inc. 2005 Stock Incentive Plan (incorporated by reference filed together with the Company’s definitive proxy statement on Schedule 14A, filed April 27, 2018. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☒ Defin
March 14, 2018	10-K	GHDX / Genomic Health, Inc. 10-K (Annual Report) Table of Contents taxane UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 14, 2018	EX-12.1	Statement Regarding Computation of Ratios. EXHIBIT 12.1 GENOMIC HEALTH, INC. STATEMENT REGARDING COMPUTATION OF RATIOS (in thousands) Year ended December 31 2013 2014 2015 2016 2017 Earnings (deficiency): Net income (loss) before income taxes $ (12,411) $ (24,199) $ (34,304) $ (12,538) $ (2,353) Add: Fixed charges 335 403 453 626 689 Earnings (deficiency) $ 12,076 $ (23,796) $ 33,851 $ 11,913 $ 1,664 Fixed Charges: Interest expense $ — $ —
March 14, 2018	EX-10.5	Genomic Health, Inc. Severance Plan for Executive Management, as amended. Exhibit 10.5 Approved by the Genomic Health Board of Directors on November 6, 2017 GENOMIC HEALTH, INC. SEVERANCE PLAN FOR EXECUTIVE MANAGEMENT The Board of Directors of Genomic Health, Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to secure the continued services, dedication, and objectivity of certain officers an
March 14, 2018	EX-21.1	List of Subsidiaries. Exhibit 21.1 GENOMIC HEALTH, INC. SUBSIDIARIES (as of December 31, 2017) Genomic Health International Holdings, LLC—100% owned by Genomic Heath, Inc. Oncotype Laboratories, Inc. (inactive)—100% owned by Genomic Health, Inc. Genomic Health International Sarl—100% owned by Genomic Health International Holdings, LLC Genomic Health UK, Ltd—100% owned by Genomic Health International Holdings, LLC Genom
March 14, 2018	EX-10.5.1	Genomic Health, Inc. Severance Plan for Executive Management, International Version. EX-10.5.1 3 ghdx-20171231ex1051b0d0b.htm EX-10.5.1 Exhibit 10.5.1 Approved by the Genomic Health Board of Directors on November 6, 2017 GENOMIC HEALTH, INC. SEVERANCE PLAN FOR EXECUTIVE MANAGEMENT INTERNATIONAL VERSION The Board of Directors of Genomic Health, Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to secure
March 12, 2018	EX-99.2	Loan Agreement Between Baker Brothers Life Sciences, L.P., 667, L.P., 14159, L.P., and Baker Bros. Advisors LP Exhibit 99.2 Loan Agreement Between Baker Brothers Life Sciences, L.P., 667, L.P., 14159, L.P., and Baker Bros. Advisors LP For value received, Baker Bros Advisors LP (the “Management Company”) promises to pay Baker Brothers Life Sciences, L.P., 667, L.P., and 14159, L.P., (collectively “The Funds”), the amounts set forth in Schedule A below, payable on the Due Date (as defined below) with interes
March 12, 2018	SC 13D/A	GHDX / Genomic Health, Inc. / Baker Brothers Advisors LP - AMENDMENT NO. 33 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.
March 12, 2018	EX-99.1	PROCEEDS AGREEMENT Exhibit 99.1 PROCEEDS AGREEMENT AGREEMENT dated as of March 8, 2018 by and between Baker Bros. Advisors LP (the “Management Company”) and Julian Baker (the “Agent”). WHEREAS, the Agent, in his capacity as a director of Genomic Health, Inc. (the “Company”), received non-transferable options (the “Options”) to purchase 8,250 shares of the Company common stock (the “Stock”) according to the below Sch
March 8, 2018	EX-99.1	Genomic Health Announces 2017 Fourth Quarter and Year-end Financial Results, Provides 2018 Financial Outlook Achieved $1.9M Profit in the Fourth Quarter; Reported Net Loss of $3.9M for the Full Year Delivered $0.4M Full-year Profit on a Non-GAAP Basi Exhibit 99.1 Contacts: Investors: Emily Faucette Genomic Health 650-569-2824 [email protected] Media: Victoria Steiner Genomic Health 415-370-5804 [email protected] Genomic Health Announces 2017 Fourth Quarter and Year-end Financial Results, Provides 2018 Financial Outlook Achieved $1.9M Profit in the Fourth Quarter; Reported Net Loss of $3.9M for the Full Year Delivered $0.4M Full
March 8, 2018	8-K/A	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2018 GENOMIC HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 000-51541 77-0552594 (State or other jurisdiction (Commission (IRS Employer of inc
March 8, 2018	EX-99.1	Genomic Health Announces 2017 Fourth Quarter and Year-end Financial Results, Provides 2018 Financial Outlook Achieved $1.9M Profit in the Fourth Quarter; Reported Net Loss of $3.9M for the Full Year Delivered $0.4M Full-year Profit on a Non-GAAP Basi Exhibit 99.1 Contacts: Investors: Emily Faucette Genomic Health 650-569-2824 [email protected] Media: Victoria Steiner Genomic Health 415-370-5804 [email protected] Genomic Health Announces 2017 Fourth Quarter and Year-end Financial Results, Provides 2018 Financial Outlook Achieved $1.9M Profit in the Fourth Quarter; Reported Net Loss of $3.9M for the Full Year Delivered $0.4M Full
March 8, 2018	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2018 GENOMIC HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 000-51541 77-0552594 (State or other jurisdiction (Commission (IRS Employer of incor
December 6, 2017	EX-3.1	Amended and Restated Bylaws of the Company, as amended December 5, 2017 (incorporated by reference to exhibit 3.1 to the Company’s Current Report on Form 8‑K filed on December 6, 2017). Exhibit 3.1 AMENDED AND RESTATED B Y L A W S OF GENOMIC HEALTH, INC. (a Delaware corporation) (as amended December 5, 2017) TABLE OF CONTENTS Page ARTICLE 1 Offices 1 1.1 Registered Office 1 1.2 Other Offices 1 ARTICLE 2 Meeting of Stockholders 1 2.1 Place of Meeting 1 2.2 Annual Meeting 1 2.3 Special Meetings 4 2.4 Notice of Meetings 4 2.5 List of Stockholders 5 2.6 Organization and Conduct of Bu
December 6, 2017	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2017 (December 5, 2017) GENOMIC HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 000-51541 77-0552594 (State or other jurisdiction (Commission
November 9, 2017	EX-10.1	Genomic Health, Inc. Deferred Compensation Plan (incorporated by reference to exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2017). Exhibit 10.1 GENOMIC HEALTH, INC. DEFERRED COMPENSATION PLAN Genomic Health, Inc., a Delaware corporation (the “Company”), hereby establishes the Genomic Health, Inc. Deferred Compensation Plan (the “Plan”), effective January 1, 2018 (the “Effective Date”), for the purpose of attracting and retaining high quality executives and Directors, and promoting in them increased efficiency and an interest
November 9, 2017	10-Q	GHDX / Genomic Health, Inc. 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 Or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-51541
November 8, 2017	EX-99.1	Genomic Health Announces Third Quarter 2017 Financial Results and Reports Recent Business Progress Delivered 2 Percent Increase in Revenue; 5 Percent Increase in Test Volume Reported Net Loss of $2.2M; Delivered $1.1M Profit on a Non-GAAP Basis Annou ghdxEx99-1 Exhibit 99.1 Investor and Media Contact: Emily Faucette Genomic Health 650-569-2824 [email protected] Genomic Health Announces Third Quarter 2017 Financial Results and Reports Recent Business Progress Delivered 2 Percent Increase in Revenue; 5 Percent Increase in Test Volume Reported Net Loss of $2.2M; Delivered $1.1M Profit on a Non-GAAP Basis Announced Collaboration with Bio
November 8, 2017	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition ghdxCurrentfolio8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
September 28, 2017	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2017 (September 26, 2017) GENOMIC HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 000-51541 77-0552594 (State or other jurisdiction (Commiss
September 13, 2017	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2017 (September 12, 2017) GENOMIC HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 000-51541 77-0552594 (State or other jurisdiction (Commiss
September 13, 2017	EX-99.1	Genomic Health and Biocartis Announce Agreement to Develop an Idylla™ IVD Oncotype DX® Breast Cancer Test to Broaden Global Patient Access Strategic Collaboration Aimed at Exclusive Test Development and Commercialization of Proprietary Genomic Health Exhibit 99.1 PRESS RELEASE Genomic Health and Biocartis Announce Agreement to Develop an Idylla? IVD Oncotype DX? Breast Cancer Test to Broaden Global Patient Access Strategic Collaboration Aimed at Exclusive Test Development and Commercialization of Proprietary Genomic Health Tests on the Idylla? Platform REDWOOD CITY, Calif., and MECHELEN, Belgium, September 13, 2017 ? Genomic Health, Inc. (NASD
August 31, 2017	8-K/A	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2017 (June 15, 2017) GENOMIC HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware (State or Other Jurisdiction of Incorporation) 000-51541 (Commis
August 4, 2017	EX-10.3	Genomic Health, Inc. Employee Stock Purchase Plan, as amended. Exhibit 10.3 GENOMIC HEALTH, INC. EMPLOYEE STOCK PURCHASE PLAN (As amended on January 31, 2017) Table of Contents Page SECTION 1 Purpose Of The Plan. 1 SECTION 2 Definitions. 1 (a) “Board” 1 (b) “Code” 1 (c) “Committee” 1 (d) “Company” 1 (e) “Compensation” 1 (f) “Corporate Reorganization” 1 (g) “Eligible Employee” 1 (h) “Exchange Act” 2 (i) “Fair Market Value” 2 (j) “Offering” 2 (k) “Offering Date
August 4, 2017	10-Q	GHDX / Genomic Health, Inc. 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 Or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-51541 GENOM
August 4, 2017	EX-10.2	Amended and Restated Genomic Health, Inc. 2005 Stock Incentive Plan (incorporated by reference to exhibit 10.2 filed with the Company’s Quarterly Report on Form 10‑Q for the quarterly period ended June 30, 2017). Exhibit 10.2 GENOMIC HEALTH, INC. AMENDED AND RESTATED 2005 STOCK INCENTIVE PLAN (As amended on January 31, 2017) Table of Contents Page SECTION 1. ESTABLISHMENT AND PURPOSE. 1 SECTION 2. DEFINITIONS. 1 (a) “Affiliate” 1 (b) “Award” 1 (c) “Board of Directors” 1 (d) “Change in Control” 1 (e) “Code” 2 (f) “Committee” 2 (g) “Company” 2 (h) “Consultant” 3 (i) “Employee” 3 (j) “Exchange Act” 3 (k) “Exe
August 1, 2017	EX-99.1	Genomic Health Announces Second Quarter 2017 Financial Results and Reports Recent Business Progress Delivered 9 Percent Increase in Test Volume; 4 Percent Increase in Revenue Continued to Generate Strong Test Demand with 5 Percent Increase in U.S. In ghdxEx99-1 Exhibit 99.1 Investor and Media Contact: Emily Faucette Genomic Health 650-569-2824 [email protected] Genomic Health Announces Second Quarter 2017 Financial Results and Reports Recent Business Progress Delivered 9 Percent Increase in Test Volume; 4 Percent Increase in Revenue Continued to Generate Strong Test Demand with 5 Percent Increase in U.S. Invasive Breast Cancer, 38 Pe
August 1, 2017	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2017 GENOMIC HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 000-51541 77-0552594 (State or other jurisdiction (Commission (IRS Employer of inco
June 19, 2017	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2017 GENOMIC HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware (State or Other Jurisdiction of Incorporation) 000-51541 (Commission File Number) 77
June 1, 2017	SC 13D/A	GHDX / Genomic Health, Inc. / Baker Brothers Advisors LP - AMENDMENT NO. 32 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 32) Genomic Health, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 37244C101 (CUSIP Number) Alexandra A. Toohey Chief Financial Officer Baker Bros. Advisors LP 667 Madison Avenue, 21st Floor New York, NY 10065
June 1, 2017	EX-99.2	Loan Agreement Between Baker Brothers Life Sciences, L.P., 667, L.P., 14159, L.P., and Baker Bros. Advisors LP EX-99.2 3 v468171ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Loan Agreement Between Baker Brothers Life Sciences, L.P., 667, L.P., 14159, L.P., and Baker Bros. Advisors LP For value received, Baker Bros Advisors LP (the “Management Company”) promises to pay Baker Brothers Life Sciences, L.P., 667, L.P., and 14159, L.P., (collectively “The Funds”), the amounts set forth in Schedule A below, payable on the
June 1, 2017	EX-99.1	PROCEEDS AGREEMENT Exhibit 99.1 PROCEEDS AGREEMENT AGREEMENT dated as of May 31, 2017 by and between Baker Bros. Advisors LP (the “Management Company”) and Julian Baker (the “Agent”). WHEREAS, the Agent, in his capacity as a director of Genomic Health, Inc. (the “Company”), received non-transferable options (the “Options”) to purchase 8,250 shares of the Company common stock (the “Stock”) according to the below Sche
May 19, 2017	EX-10.1	Form of Indemnification Agreement between the Company and its officers and directors (incorporated by reference to exhibit 10.1 filed with the Company’s Current Report on Form 8-K filed on May 19, 2017). Exhibit 10.1 INDEMNIFICATION AGREEMENT This Indemnification Agreement (the ?Agreement?), is dated as of , 20 between Genomic Health, Inc., a Delaware corporation (the ?Corporation?), and (?Indemnitee?). W I T N E S S E T H: WHEREAS, Indemnitee is either a member of the board of directors of the Corporation (the ?Board of Directors?) or an officer of the Corporation, or both, and in such capacity o
May 19, 2017	8-K	Genomic Health 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2017 GENOMIC HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 000-51541 77-0552594 (State or other jurisdiction (Commission (IRS Employer of incorp
May 10, 2017	10-Q	Genomic Health 10-Q (Quarterly Report) ghdxCurrent folio10Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
May 9, 2017	EX-99.1	Genomic Health Announces First Quarter 2017 Financial Results and Reports Recent Business Progress Delivered 7 Percent Increase in Test Volume; 4 Percent Increase in Revenue Generated 17 Percent Test Growth and 29 Percent Revenue Growth Across Intern Exhibit 99.1 Contacts: Investors: Emily Faucette Genomic Health 650-569-2824 [email protected] Media: Victoria Steiner Genomic Health 650-569-2499 [email protected] Genomic Health Announces First Quarter 2017 Financial Results and Reports Recent Business Progress Delivered 7 Percent Increase in Test Volume; 4 Percent Increase in Revenue Generated 17 Percent Test Growth and 29 Perce
May 9, 2017	8-K	Genomic Health 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2017 GENOMIC HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 000-51541 77-0552594 (State or other jurisdiction (Commission (IRS Employer of incorpo
April 28, 2017	DEF 14A	Genomic Health DEF 14A ghdxCurrentFolioDEF14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 15, 2017	10-K	Genomic Health 10-K (Annual Report) ghdxCurrent folio10K Table of Contents taxane UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 15, 2017	EX-21.1	GENOMIC HEALTH, INC. (as of December 31, 2016) Exhibit 21.1 GENOMIC HEALTH, INC. SUBSIDIARIES (as of December 31, 2016) Genomic Health International Holdings, LLC—100% owned by Genomic Heath, Inc. Oncotype Laboratories, Inc. (inactive)—100% owned by Genomic Health, Inc. Genomic Health International Sarl—100% owned by Genomic Health International Holdings, LLC Genomic Health UK, Ltd—100% owned by Genomic Health International Holdings, LLC Genom
March 15, 2017	EX-12.1	GENOMIC HEALTH, INC. STATEMENT REGARDING COMPUTATION OF RATIOS (in thousands) EXHIBIT 12.1 GENOMIC HEALTH, INC. STATEMENT REGARDING COMPUTATION OF RATIOS (in thousands) Year ended December 31 2012 2013 2014 2015 2016 Earnings (deficiency): Net income (loss) before income taxes $ 8,671 $ (12,411) $ (24,199) $ (34,304) $ (12,538) Add: Fixed charges 408 335 403 453 626 Earnings (deficiency) $ 9,079 $ (12,076) $ (23,796) $ (33,851) $ (11,912) Fixed Charges: Interest expense $ —
February 14, 2017	8-K	Genomic Health 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2017 GENOMIC HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 000-51541 77-0552594 (State or other jurisdiction (Commission (IRS Employer of i
February 14, 2017	EX-99.1	Genomic Health Announces 2016 Fourth Quarter and Year-End Financial Results, Provides 2017 Financial Outlook Achieved Profit in the Fourth Quarter of 2016; Guides to Full Year Profit in 2017 Delivered 14 Percent Revenue Growth and 11 Percent Test Gro Exhibit 99.1 Contacts: Investors: Emily Faucette Genomic Health 650-569-2824 [email protected] Media: Victoria Steiner Genomic Health 650-569-2499 [email protected] Genomic Health Announces 2016 Fourth Quarter and Year-End Financial Results, Provides 2017 Financial Outlook Achieved Profit in the Fourth Quarter of 2016; Guides to Full Year Profit in 2017 Delivered 14 Percent Revenue
February 10, 2017	SC 13G/A	NVTA / Invitae Corp. / GENOMIC HEALTH INC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* INVITAE CORPORATION (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 46185L103 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan
December 15, 2016	8-K	Genomic Health 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2016 GENOMIC HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 000-51541 77-0552594 (State or other jurisdiction (Commission (IRS Employer of i
November 4, 2016	10-Q	Genomic Health 10-Q (Quarterly Report) ghdxCurrent folio10Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
November 1, 2016	EX-99.1	Genomic Health Reports Third Consecutive Quarter of Double-Digit Revenue Growth in Announcement of Third Quarter 2016 Financial Results 12% Increase in Revenue; 8% Increase in Tests Delivered 18% Constant Currency Increase in International Revenue an Exhibit 99.1 Contacts: Investors: Emily Faucette Genomic Health 650-569-2824 [email protected] Media: Victoria Steiner Genomic Health 650-569-2499 [email protected] Genomic Health Reports Third Consecutive Quarter of Double-Digit Revenue Growth in Announcement of Third Quarter 2016 Financial Results 12% Increase in Revenue; 8% Increase in Tests Delivered 18% Constant Currency Incre
November 1, 2016	8-K	Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 a16-2087018k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2016 GENOMIC HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 000-51541 77-0552594 (State or other jurisdiction (Com
August 25, 2016	424B3	13,650,835 Shares GENOMIC HEALTH, INC. Common Stock Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents Filed pursuant to Rule 424(b)(3) File No.
August 25, 2016	424B3	13,650,835 Shares GENOMIC HEALTH, INC. Common Stock Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents Filed pursuant to Rule 424(b)(3) File No.
August 25, 2016	424B3	$350,000,000 GENOMIC HEALTH, INC. Debt Securities Common Stock Preferred Stock Depositary Shares Warrants Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents Filed pursuant to Rule 424(b)(3) File No.
August 25, 2016	424B3	$350,000,000 GENOMIC HEALTH, INC. Debt Securities Common Stock Preferred Stock Depositary Shares Warrants Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents Filed pursuant to Rule 424(b)(3) File No.
August 23, 2016	CORRESP	Genomic Health ESP Genomic Health, Inc. 301 Penobscot Drive Redwood City, California 94063 August 23, 2016 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-0409 Attention: John Reynolds Ronald E. Alper RE: Genomic Health, Inc. Registration Statement on Form S-3 File No. 333-213074 Request for Acceleration of Effectiveness Ladies and Gentlemen: Pursuant to Rule 461
August 23, 2016	CORRESP	Genomic Health ESP Genomic Health, Inc. 301 Penobscot Drive Redwood City, California 94063 August 23, 2016 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-0409 Attention: John Reynolds Ronald E. Alper RE: Genomic Health, Inc. Registration Statement on Form S-3 File No. 333-213076 Request for Acceleration of Effectiveness Ladies and Gentlemen: Pursuant to Rule 461
August 23, 2016	CORRESP	Genomic Health ESP Genomic Health, Inc. 301 Penobscot Drive Redwood City, California 94063 August 23, 2016 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-0409 Attention: John Reynolds Ronald E. Alper RE: Genomic Health, Inc. Registration Statement on Form S-3 File No. 333-213076 Request for Acceleration of Effectiveness Ladies and Gentlemen: Pursuant to Rule 461
August 23, 2016	CORRESP	Genomic Health ESP Genomic Health, Inc. 301 Penobscot Drive Redwood City, California 94063 August 23, 2016 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-0409 Attention: John Reynolds Ronald E. Alper RE: Genomic Health, Inc. Registration Statement on Form S-3 File No. 333-213074 Request for Acceleration of Effectiveness Ladies and Gentlemen: Pursuant to Rule 461
August 15, 2016	SC 13D/A	GHDX / Genomic Health, Inc. / BAKER JULIAN - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 31) Genomic Health, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 37244C101 (CUSIP Number) Alexandra A. Toohey Chief Financial Officer Baker Bros. Advisors LP 667 Madison Avenue, 21st Floor New York, NY 10065
August 15, 2016	SC 13D/A	GHDX / Genomic Health, Inc. / BAKER JULIAN - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 31) Genomic Health, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 37244C101 (CUSIP Number) Alexandra A. Toohey Chief Financial Officer Baker Bros. Advisors LP 667 Madison Avenue, 21st Floor New York, NY 10065
August 11, 2016	S-8	Genomic Health S-8 As filed with the Securities and Exchange Commission on August 11, 2016. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GENOMIC HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 77-0552594 (State or other jurisdiction of (I.R.S. Employer incorporation or organi
August 11, 2016	S-3	Genomic Health S-3 Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents As filed with the Securities and Exchange Commission on August 11, 2016 Registration No.
August 11, 2016	EX-12.1	GENOMIC HEALTH, INC. STATEMENT REGARDING COMPUTATION OF RATIOS (in thousands) QuickLinks - Click here to rapidly navigate through this document EXHIBIT 12.1 GENOMIC HEALTH, INC. STATEMENT REGARDING COMPUTATION OF RATIOS (in thousands) Year ended December 31, 2011 2012 2013 2014 2015 Six Months ended June 30, 2016 Earnings (deficiency): Net income (loss) before income taxes $ 8,275 $ 8,671 $ (12,411 ) $ (24,199 ) $ (34,304 ) $ (11,794 ) Add: Fixed charges 239 408 335 403 453
August 11, 2016	S-3	Genomic Health S-3 Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents As filed with the Securities and Exchange Commission on August 11, 2016 Registration No.
August 11, 2016	EX-4.1	GENOMIC HEALTH, INC. [ ] Dated as of , 20 Exhibit 4.1 GENOMIC HEALTH, INC. TO [ ] Trustee Indenture Dated as of , 20 GENOMIC HEALTH, INC. Reconciliation and tie between Trust Indenture Act of 1939 and Indenture, dated as of , 20 Trust Indenture Indenture Act Section Sections ? 310(a)(1) 609 (a)(2) 609 (a)(3) Not Applicable (a)(4) Not Applicable (a)(5) 609 (b) 608 610 ? 311(a) 613(a) (b) 613(b) (b)(2) 703(a)(2) 703(b) ? 312(a) 701 702(a) (
August 11, 2016	SC 13D/A	GHDX / Genomic Health, Inc. / BAKER JULIAN - AMENDMENT NO. 30 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 30) Genomic Health, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 37244C101 (CUSIP Number) Alexandra A. Toohey Chief Financial Officer Baker Bros. Advisors LP 667 Madison Avenue, 21st Floor New York, NY 10065
August 9, 2016	10-Q	Genomic Health 10-Q (Quarterly Report) ghdxCurrent folio10Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
August 9, 2016	EX-10.2	Registration Rights Agreement dated as of August 8, 2016, between the Company and Baker Bros. Investments, L.P., Baker Bros. Investments II, L.P., 667, L.P., Baker Brothers Life Sciences, L.P., 14159, L.P. and Baker/Tisch Investments, L.P. (incorporated by reference to exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2016). Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made as of August 8, 2016, by and between Genomic Health, Inc., a Delaware corporation (the “Company”), and the persons listed on the attached Schedule A who are signatories to this Agreement (collectively, the “Investors”). Unless otherwise defined herein, capitalized terms used in this Agreement h
August 9, 2016	EX-10.1	GENOMIC HEALTH, INC. AMENDED AND RESTATED 2005 STOCK INCENTIVE PLAN (Adopted by the Board on September 8, 2005, and amended and restated by the Board on January 26, 2016) EX-10.1 2 ghdx-20160630ex1010607bb.htm EX-10.1 Exhibit 10.1 GENOMIC HEALTH, INC. AMENDED AND RESTATED 2005 STOCK INCENTIVE PLAN (Adopted by the Board on September 8, 2005, and amended and restated by the Board on January 26, 2016) Table of Contents Page SECTION 1. ESTABLISHMENT AND PURPOSE. 1 SECTION 2. DEFINITIONS. 1 (a) “Affiliate” 1 (b) “Award” 1 (c) “Board of Directors” 1 (d) “Change in Contro
August 2, 2016	EX-99.1	Genomic Health Reports Continued Double-Digit Growth in Announcement of Second Quarter 2016 Financial Results, Raises Low End of Full-Year Test and Revenue Guidance 16% Increase in Revenue; 12% Increase in Tests Delivered 13% Growth with Record Numbe Exhibit 99.1 Contacts: Investors: Emily Faucette Genomic Health 650-569-2824 [email protected] Media: Victoria Steiner Genomic Health 650-569-2499 [email protected] Genomic Health Reports Continued Double-Digit Growth in Announcement of Second Quarter 2016 Financial Results, Raises Low End of Full-Year Test and Revenue Guidance 16% Increase in Revenue; 12% Increase in Tests Deliver
August 2, 2016	8-K	Genomic Health 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2016 GENOMIC HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 000-51541 77-0552594 (State or other jurisdiction (Commission (IRS Employer of inco
June 23, 2016	8-K	Genomic Health 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2016 GENOMIC HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 000-51541 77-0552594 (State or other jurisdiction (Commission (IRS Employer of incor
June 15, 2016	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2016 GENOMIC HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware (State or Other Jurisdiction of Incorporation) 000-51541 (Commission File Number) 77-
May 19, 2016	EX-99.1	PROCEEDS AGREEMENT Exhibit 99.1 PROCEEDS AGREEMENT AGREEMENT dated as of May 16, 2016 by and between Baker Bros. Advisors LP (the “Management Company”) and Julian Baker (the “Agent”). WHEREAS, the Agent, in his capacity as a director of Genomic Health, Inc. (the “Company”), received non-transferable options (the “Options”) to purchase 8,250 shares of the Company common stock (the “Stock”) according to the below Sche
May 19, 2016	SC 13D/A	GHDX / Genomic Health, Inc. / BAKER JULIAN - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 29) Genomic Health, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 37244C101 (CUSIP Number) Alexandra A. Toohey Chief Financial Officer Baker Bros. Advisors LP 667 Madison Avenue, 21st Floor New York, NY 10065
May 19, 2016	EX-99.2	Loan Agreement Between Baker Brothers Life Sciences, L.P., 667, L.P., 14159, L.P., and Baker Bros. Advisors LP EX-99.2 3 v440517ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Loan Agreement Between Baker Brothers Life Sciences, L.P., 667, L.P., 14159, L.P., and Baker Bros. Advisors LP For value received, Baker Bros Advisors LP (the “Management Company”) promises to pay Baker Brothers Life Sciences, L.P., 667, L.P., and 14159, L.P., (collectively “The Funds”), the amounts set forth in Schedule A below, payable on the
May 9, 2016	10-Q	Genomic Health 10-Q (Quarterly Report) ghdxCurrent folio10Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
May 4, 2016	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2016 GENOMIC HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 000-51541 77-0552594 (State or other jurisdiction (Commission (IRS Employer of incorpo
May 4, 2016	EX-99.1	Genomic Health Reports Double-Digit Revenue and Test Growth in Announcement of First Quarter 2016 Financial Results 19% Increase in Revenue; 16% Increase in Tests Delivered Unparalleled Prospective Outcomes Evidence Drives Further Growth in U.S. Inva Exhibit 99.1 Contacts: Investors: Emily Faucette Genomic Health 650-569-2824 [email protected] Media: Victoria Steiner Genomic Health 650-569-2499 [email protected] Genomic Health Reports Double-Digit Revenue and Test Growth in Announcement of First Quarter 2016 Financial Results 19% Increase in Revenue; 16% Increase in Tests Delivered Unparalleled Prospective Outcomes Evidence Dri
April 28, 2016	DEFA14A	Genomic Health DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin
April 25, 2016	DEF 14A	Genomic Health DEF 14A Use these links to rapidly review the document Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 9, 2016	10-K	Genomic Health 10-K (Annual Report) ghdxCurrent folio10K Table of Contents taxane UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 9, 2016	EX-10.8.2	Third Amendment to Lease dated September 23, 2005 between the Company and Metropolitan Life Insurance Company (incorporated by reference to exhibit 10.8.2 filed with the Company’s Annual Report on Form 10‑K for the year ended December 31, 2015). Exhibit 10.8.2 THIRD AMENDMENT TO LEASE This Third Amendment to Lease (“Amendment”) is entered into, and dated for reference purposes, as of November 11, 2015 (the “Execution Date”) by and between METROPOLITAN LIFE INSURANCE COMPANY, a New York corporation (“Landlord”), and GENOMIC HEALTH, INC., a Delaware corporation (“Tenant”), with reference to the following facts (“Recitals”): A. Landlord and
March 9, 2016	EX-10.9.2	Second Amendment to Lease dated January 4, 2007 between the Company and Metropolitan Life Insurance Company (incorporated by reference to exhibit 10.9.2 filed with the Company’s Annual Report on Form 10‑K for the year ended December 31, 2015). EX-10.9.2 6 ghdx-20151231ex10927f13d.htm EX-10.9.2 Exhibit 10.9.2 SECOND AMENDMENT TO LEASE This Second Amendment to Lease (“Amendment”) is entered into, and dated for reference purposes, as of November 11, 2015 (the “Execution Date”) by and between METROPOLITAN LIFE INSURANCE COMPANY, a New York corporation (“Landlord”), and GENOMIC HEALTH, INC., a Delaware corporation (“Tenant”), with reference
March 9, 2016	EX-10.10.1	First Amendment to Lease dated October 1, 2009 between the Company and Metropolitan Life Insurance Company (incorporated by reference to exhibit 10.10.1 filed with the Company’s Annual Report on Form 10‑K for the year ended December 31, 2015). Exhibit 10.10.1 FIRST AMENDMENT TO LEASE This First Amendment to Lease (“Amendment”) is entered into, and dated for reference purposes, as of November 11, 2015 (the “Execution Date”) by and between METROPOLITAN LIFE INSURANCE COMPANY, a New York corporation (“Landlord”), and GENOMIC HEALTH, INC., a Delaware corporation (“Tenant”), with reference to the following facts (“Recitals”): A. Landlord and
March 9, 2016	EX-10.12	Lease dated November 11, 2015 between the Company and Metropolitan Life Insurance Company (incorporated by reference to exhibit 10.12 filed with the Company’s Annual Report on Form 10‑K for the year ended December 31, 2015). Exhibit 10.12 LEASE BETWEEN METROPOLITAN LIFE INSURANCE COMPANY (LANDLORD) AND GENOMIC HEALTH, INC. (TENANT) SEAPORT CENTRE Redwood City, California Error! Unknown document property name. TABLE OF CONTENTS PAGE ARTICLE ONE - BASIC LEASE PROVISIONS 1 1.01 BASIC LEASE PROVISIONS 1 1.02 ENUMERATION OF EXHIBITS & RIDER(S) 2 1.03 DEFINITIONS 2 ARTICLE TWO - PREMISES, TERM, FAILURE TO GIVE POSSESSION, C
March 9, 2016	EX-21.1	GENOMIC HEALTH, INC. Exhibit 21.1 GENOMIC HEALTH, INC. SUBSIDIARIES Genomic Health International Holdings, LLC—100% owned by Genomic Heath, Inc. Oncotype Laboratories, Inc. (inactive)—100% owned by Genomic Health, Inc. Genomic Health International Sarl—100% owned by Genomic Health International Holdings, LLC Genomic Health UK, Ltd—100% owned by Genomic Health International Holdings, LLC Genomic Health Deutschland GmbH
March 9, 2016	EX-10.11.2	Second Amendment to Lease dated August 30, 2013 between the Company and Metropolitan Life Insurance Company (incorporated by reference to exhibit 10.11.2 filed with the Company’s Annual Report on Form 10‑K for the year ended December 31, 2015). EX-10.11.2 3 ghdx-20151231ex101129b60.htm EX-10.11.2 Exhibit 10.11.2 SECOND AMENDMENT TO LEASE This Second Amendment to Lease (“Amendment”) is entered into, and dated for reference purposes, as of November 11, 2015 (the “Execution Date”) by and between METROPOLITAN LIFE INSURANCE COMPANY, a New York corporation (“Landlord”), and GENOMIC HEALTH, INC., a Delaware corporation (“Tenant”), with referen
February 22, 2016	8-K	Genomic Health 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2016 GENOMIC HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 000-51541 77-0552594 (State or other jurisdiction (Commission (IRS Employer of i
February 12, 2016	SC 13G/A	GHDX / Genomic Health, Inc. / Camber Capital Management LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) Genomic Health Inc. (Name of Issuer) Common Shares, $0.0001 par value (Title of Class of Securities) 37244C101 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan
February 12, 2016	EX-1	JOINT FILING AGREEMENT EXHIBIT 1 JOINT FILING AGREEMENT This Joint Filing Agreement dated February 12, 2016 is by and between Camber Capital Management LLC, a Massachusetts limited liability company, and Stephen DuBois, an individual (the foregoing are collectively referred to herein as the "Filers").
February 12, 2016	SC 13G	NVTA / Invitae Corp. / GENOMIC HEALTH INC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* INVITAE CORPORATION (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 46185L103 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant
February 10, 2016	EX-99.1	Genomic Health Announces 2016 Financial Outlook and Provides 2015 Fourth Quarter and Year-End Financial Results Expects to Deliver Double-Digit Test and Revenue Growth in 2016 Plans to Launch First Liquid Biopsy Test Mid-2016 Conference Call Today at EX-99.1 2 a16-39671ex99d1.htm EX-99.1 Exhibit 99.1 Contacts: Investors: Emily Faucette Genomic Health 650-569-2824 [email protected] Media: Victoria Steiner Genomic Health 650-569-2499 [email protected] Genomic Health Announces 2016 Financial Outlook and Provides 2015 Fourth Quarter and Year-End Financial Results Expects to Deliver Double-Digit Test and Revenue Growth in 2016 Plans
February 10, 2016	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2016 GENOMIC HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 000-51541 77-0552594 (State or other jurisdiction (Commission (IRS Employer of i
January 8, 2016	EX-99.1	# # # Exhibit 99.1 Contacts: Investors: Emily Faucette Genomic Health 650-569-2824 [email protected] Media: Victoria Steiner Genomic Health 415-370-5804 [email protected] Genomic Health Announces Preliminary 2015 Revenue and Confirms 2016 Growth Expectations REDWOOD CITY, Calif., January 8, 2016 Genomic Health, Inc. (Nasdaq: GHDX) today announced preliminary revenue for the year ended
January 8, 2016	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2016 GENOMIC HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 000-51541 77-0552594 (State or other jurisdiction (Commission (IRS Employer of inc
November 9, 2015	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) 10-Q/A 1 ghdx-20150930x10qa.htm 10-Q/A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2015 Or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the t
November 9, 2015	S-8	Genomic Health S-8 As filed with the Securities and Exchange Commission on November 9, 2015. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GENOMIC HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 77-0552594 (State or other jurisdiction of (I.R.S. Employer incorporation or organ
November 5, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 10-Q 1 ghdx-20150930x10q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2015 Or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to
November 3, 2015	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 a15-2225318k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2015 GENOMIC HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 000-51541 77-0552594 (State or other jurisdiction (Com
November 3, 2015	EX-99.1	Genomic Health Reports Highest Test Growth in Two Years in Announcement of Third Quarter 2015 Financial Results 17% Increase in Tests Delivered; 6% Increase in Revenue Continued Strong Growth in U.S. Breast Cancer Business with 11% Increase in Test V Exhibit 99.1 Contacts: Investors: Emily Faucette Genomic Health 650-569-2824 [email protected] Media: Victoria Steiner Genomic Health 650-569-2499 [email protected] Genomic Health Reports Highest Test Growth in Two Years in Announcement of Third Quarter 2015 Financial Results 17% Increase in Tests Delivered; 6% Increase in Revenue Continued Strong Growth in U.S. Breast Cancer Busin
August 6, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2015 Or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-51541 GENOM
August 6, 2015	EX-10.1	GENOMIC HEALTH, INC. 2005 STOCK INCENTIVE PLAN (Adopted by the Board on September 8, 2005, and amended and restated by the Board on April 25, 2015) Exhibit 10.1 GENOMIC HEALTH, INC. 2005 STOCK INCENTIVE PLAN (Adopted by the Board on September 8, 2005, and amended and restated by the Board on April 25, 2015) Genomic Health, Inc. 2005 Stock Incentive Plan Table of Contents Page SECTION 1. ESTABLISHMENT AND PURPOSE. 1 SECTION 2. DEFINITIONS. 1 (a) “Affiliate” 1 (b) “Award” 1 (c) “Board of Directors” 1 (d) “Change in Control” 1 (e) “Code” 2 (f) “
August 4, 2015	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 a15-1691418k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2015 GENOMIC HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 000-51541 77-0552594 (State or other jurisdiction (Commi
August 4, 2015	EX-99.1	Genomic Health Announces Second Quarter 2015 Financial Results and Reports Record International and Prostate Cancer Tests Delivered 8% Increase in Total Tests Delivered; 13% Increase in International Tests Delivered; More than Double Prostate Tests D Exhibit 99.1 Contacts: Investors: Emily Faucette Genomic Health 650-569-2824 [email protected] Media: Victoria Steiner Genomic Health 650-569-2499 [email protected] Genomic Health Announces Second Quarter 2015 Financial Results and Reports Record International and Prostate Cancer Tests Delivered 8% Increase in Total Tests Delivered; 13% Increase in International Tests Delivered; Mo
June 17, 2015	8-K	Genomic Health 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2015 GENOMIC HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware (State or Other Jurisdiction of Incorporation) 000-51541 (Commission File Number) 77
May 7, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 10-Q 1 ghdx-20150331x10q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2015 Or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Comm
May 7, 2015	EX-10.2	Genomic Health, Inc. Severance Plan For Executive Management Exhibit 10.2 Genomic Health, Inc. Severance Plan For Executive Management The Board of Directors of Genomic Health, Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to secure the continued services, dedication, and objectivity of certain officers and employees of the Company without concern as to whether such officers
May 5, 2015	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2015 GENOMIC HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 000-51541 77-0552594 (State or other jurisdiction (Commission (IRS Employer of incorpo
May 5, 2015	EX-99.1	Genomic Health Announces First Quarter 2015 Financial Results and Reports Record Oncotype DX® Test Volume 10% Test Volume Increase; 2% Product Revenue Increase, 3% Product Revenue Increase in Constant Currency U.S. Breast Cancer Business Continued to Exhibit 99.1 Contacts: Investors: Emily Faucette Genomic Health 650-569-2824 [email protected] Media: Victoria Steiner Genomic Health 650-569-2499 [email protected] Genomic Health Announces First Quarter 2015 Financial Results and Reports Record Oncotype DX? Test Volume 10% Test Volume Increase; 2% Product Revenue Increase, 3% Product Revenue Increase in Constant Currency U.S. Brea
April 30, 2015	DEF 14A	Genomic Health DEF 14A QuickLinks - Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
April 7, 2015	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2015 GENOMIC HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 000-51541 77-0552594 (State or other jurisdiction (Commission (IRS Employer of incor
March 12, 2015	EX-21.1	GENOMIC HEALTH, INC. Exhibit 21.1 GENOMIC HEALTH, INC. SUBSIDIARIES Genomic Health International Holdings, LLC—100% owned by Genomic Heath, Inc. Oncotype Laboratories, Inc. (inactive)—100% owned by Genomic Health, Inc. Genomic Health International Sarl—100% owned by Genomic Health International Holdings, LLC Genomic Health UK, Ltd—100% owned by Genomic Health International Holdings, LLC Genomic Health Deutschland GmbH
March 12, 2015	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10‑K 10-K 1 ghdx-20141231x10k.htm 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10‑K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2014 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fro
February 20, 2015	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2015 GENOMIC HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 000-51541 77-0552594 (State or other jurisdiction (Commission (IRS Employer of i
February 13, 2015	SC 13G/A	GHDX / Genomic Health, Inc. / Camber Capital Management LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Genomic Health Inc. (Name of Issuer) Common Shares, $0.0001 par value (Title of Class of Securities) 37244C101 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan
February 13, 2015	EX-1	JOINT FILING AGREEMENT EXHIBIT 1 JOINT FILING AGREEMENT This Joint Filing Agreement dated February 13, 2015 is by and between Camber Capital Management LLC, a Massachusetts limited liability company, and Stephen DuBois, an individual (the foregoing are collectively referred to herein as the "Filers").
February 10, 2015	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2015 GENOMIC HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 000-51541 77-0552594 (State or other jurisdiction (Commission (IRS Employer of i
February 10, 2015	EX-99.1	Genomic Health Announces Year-End 2014 Financial Results, Provides 2015 Financial Outlook 12% Increase in Full-Year Test Volume; 6% Increase in Full-Year Product Revenue NHS England Agreed to Access Program for Oncotype DX® Breast Cancer Test beginni Exhibit 99.1 Contacts: Investors: Emily Faucette Genomic Health 650-569-2824 [email protected] Media: Victoria Steiner Genomic Health 650-569-2499 [email protected] Genomic Health Announces Year-End 2014 Financial Results, Provides 2015 Financial Outlook 12% Increase in Full-Year Test Volume; 6% Increase in Full-Year Product Revenue NHS England Agreed to Access Program for Oncotype
January 30, 2015	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2015 GENOMIC HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 000-51541 77-0552594 (State or other jurisdiction (Commission (IRS Employer of in
January 30, 2015	EX-3.1	AMENDED AND RESTATED B Y L A W S GENOMIC HEALTH, INC. (a Delaware corporation) (as amended January 27, 2015) EX-3.1 2 a15-34451ex3d1.htm EX-3.1 Exhibit 3.1 AMENDED AND RESTATED B Y L A W S OF GENOMIC HEALTH, INC. (a Delaware corporation) (as amended January 27, 2015) TABLE OF CONTENTS Page ARTICLE 1 Offices 1 1.1 Registered Office 1 1.2 Other Offices 1 ARTICLE 2 Meeting of Stockholders 1 2.1 Place of Meeting 1 2.2 Annual Meeting 1 2.3 Special Meetings 4 2.4 Notice of Meetings 4 2.5 List of Stockholders 5
November 10, 2014	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2014 GENOMIC HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 000-51541 77-0552594 (State or other jurisdiction (Commission (IRS Employer of in
November 6, 2014	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2014 o TRANSITION REPORT PURSUANT Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2014 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-5154
November 6, 2014	EX-10.1	First Amendment to Lease dated August 30, 2013 between the Company and Metropolitan Life Insurance Company (incorporated by reference to exhibit 10.1 filed with the Company’s Quarterly Report on Form 10‑Q for the quarterly period ended September 30, 2014). Exhibit 10.1 FIRST AMENDMENT TO LEASE This First Amendment to Lease (“Amendment”) is entered into, and dated for reference purposes, as of June 30, 2014 (the “Execution Date”) by and between METROPOLITAN LIFE INSURANCE COMPANY, a New York corporation (“Metropolitan”), as Landlord (“Landlord”), and GENOMIC HEALTH, INC., a Delaware corporation (“Genomic”), as Tenant (“Tenant”), with reference to the
November 4, 2014	EX-99.1	Genomic Health Announces Third Quarter 2014 Financial Results and Reports Continued Growth in U.S. Invasive Breast Cancer Business 9% Increase in Test Volume; 5% Increase in Total Revenue CMS Announces Gapfill Pricing Methodology for Oncotype DX® Bre Exhibit 99.1 Contacts: Investors: Emily Faucette Genomic Health 650-569-2824 [email protected] Media: Victoria Steiner Genomic Health 650-569-2499 [email protected] Genomic Health Announces Third Quarter 2014 Financial Results and Reports Continued Growth in U.S. Invasive Breast Cancer Business 9% Increase in Test Volume; 5% Increase in Total Revenue CMS Announces Gapfill Pricing M
November 4, 2014	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2014 GENOMIC HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 000-51541 77-0552594 (State or other jurisdiction (Commission (IRS Employer of in

GHDX / Genomic Health, Inc. - SEC Filings, Annual Report, Proxy Statement

Basic Stats

SEC Filings

SEC Filings (Chronological Order)